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Objective: Nucleic acid amplification tests have facilitated field based STD studies and increased
screening activities. However, even with highly specific tests, the positive predictive value (PPV) of such
tests may be lower than desirable in low prevalence populations. We estimated PPVs for a single LCR
test in a population survey in which positive specimens were retested.
Methods: The Baltimore STD and Behavior Survey (BSBS) was a population based behavioural survey
of adults which included collecting urine specimens to assess the prevalence of gonorrhoea and
chlamydial infection. Gonorrhoea and chlamydial infection were diagnosed by ligase chain reaction
(LCR). Nearly all positive results were retested by LCR. Because of cost considerations, negative results
were not confirmed. Predicted curves for the PPV were calculated for a single testing assuming an LCR
test sensitivity of 95%, and test specificities in the range 95.0%–99.9%, for disease prevalences
between 1% and 10%. Positive specimens were retested to derive empirical estimates of the PPV of a
positive result on a single LCR test.
Results: 579 participants age 18–35 provided urine specimens. 20 (3.5%) subjects initially
tested positive for chlamydial infection, and 39 (6.7%) tested positive for gonococcal infection. If
positive results on the repeat LCR are taken as confirmation of a “true” infection, the observed PPV for
the first LCR testing was 89.5% for chlamydial infection and 83.3% for gonorrhoea. This is within the
range of theoretical PPVs calculated from the assumed sensitivities and specificities of the LCR
assays.
Conclusions: Empirical performance of a single LCR testing approximated the theoretically predicted
PPV in this field study. This result demonstrates the need to take account of the lower PPVs obtained
when such tests are used in field studies or clinical screening of low prevalence populations. Repeat
testing of specimens, preferably with a different assay (for example, polymerase chain reaction), and
disclosure of the non-trivial potential for false positive test results would seem appropriate in all such
studies.
Chlamydial infection and gonorrhoea are the two mostcommon bacterial sexually transmitted infections inthe United States,1 predominantly affecting adoles-
cents and young adults. Medical and public health
interventions require accurate diagnosis, which is easily
accomplished for symptomatic patients. Most gonococcal
and chlamydial infections in women are asymptomatic. In
male clinic populations, the literature suggests that up to 10%
of gonococcal urethritis,2 3 and a third of chlamydial urethritis
may be asymptomatic.4 In population based surveys,
however, the proportion of asymptomatic disease is higher.
Screening asymptomatic people at risk for infection
has therefore evolved as a major public health control
strategy.
New non-invasive nucleic acid amplification tests (NAATs),
such as ligase chain reaction (LCR), have been licensed for
diagnosis of gonorrhoea and chlamydial infection in urine for
both males and females.5–8 Testing of urine specimens
eliminates the need for clinical examination, and it provides
the opportunity for STD screening in community based sites,
such as schools,9 military field clinics,10 developing country
settings,11 and primary care clinics. Non-invasive screening
can also be used in population surveys, such as the ones
recently performed in Baltimore,12 in the National Survey of
Adolescent Males,13 in a pilot test of the National Health and
Nutrition Examination Survey,14 and in a study of Job Corps
participants.15
Use of NAAT results for STD diagnosis in population surveys
or other screenings of low prevalence populations is associated
with a lower positive predictive value (PPV) and higher
proportion of false positive results than one encounters in
clinical practice. This issue has been previously raised by
Schachter and Chow.16
In this paper, we report on our experience conducting a
population survey that employed LCR tests to diagnose gono-
coccal and chlamydial infections. We estimated PPVs based on
a single LCR test and compared the theoretically predicted
PPV for a single testing with the results we obtained when
positive LCR tests were retested for confirmation. Discordance
in test results across these two testings provides an empirical
measure (albeit an imperfect one) of the predictive value of a
positive result in a single LCR testing.
METHODS
Baltimore STD and Behavior Survey
The Baltimore STD and Behavioral Survey (BSBS) was a
population based cross sectional household survey of adults
residing in Baltimore, MD, USA. Survey interviews were con-
ducted with 1014 respondents ages 18–45 years between
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January 1997 and September 1998. According to the study
protocol, only respondents between 18 and 35 years of age
were asked to provide a urine specimen for gonorrhoea and
Chlamydia trachomatis testing. Of the 728 respondents aged
18–35, 579 (80%) provided a urine sample, 16% refused, and
4% were not tested (owing to interviewer error, inability to
provide a specimen, insufficient volume, etc).
For study purposes, respondents were considered positive if
both an initial and a confirmatory LCR were positive. Repeat
tests were unavailable for three cases who tested positive ini-
tially. These cases were classified as positive based on their first
testing. All respondents were given a telephone number they
could call to learn of their test results. Study staff used a suc-
cession of methods to attempt to contact participants who
were confirmed positive (telephone, registered letter, and, if
refused or undelivered, regular mail). Free, expedited treat-
ment at one of the Baltimore City Department of Health clin-
ics was offered to all contacted subjects with confirmed posi-
tive results.
Details of the full study design have been described
elsewhere.12 Protocols were approved by the institutional




Urine testing was performed following standard LCR proce-
dures detailed by the manufacturer. (LCx-Abbott Laborato-
ries, Abbott Park, IL, USA). For Neisseria gonorrhoeae, the optical
density (OD) cut offs for the LCR products were: negative =
<0.8; indeterminate: 0.8 <x<1.2; positive >1.2. For the C tra-
chomatis assay, negative results were defined as less than 0.8,
indeterminate: 0.8 <x<1.0, and positive as >1.0. All tests in
the indeterminate range were retested to provide a “first test”
result.
Second testing
We retested 19 of 20 specimens that tested positive for
chlamydial infection on their first LCR testing and 36 of 39
specimens that tested positive for gonococcal infection. Two
specimens that initially tested positive for gonococcal infec-
tion and one specimen that initially tested positive for both
gonococcal and chlamydial infections were not retested
because the original specimen was not available. We defined a
confirmed positive result as a specimen with positive results
on both initial and repeat testing. Negative tests were not con-
firmed.
Theoretical expectations for positive predictive value
The positive predictive value, which reflects the post-test
probability of disease for a positive test,17 is defined as:
PPV = probability (disease/test positive) = true positives/
(true positives + false positives)
The positive predictive value can also be expressed in a form
based on Bayes’s theorem17:
PPV = (sensitivity × prevalence)/((sensitivity × prevalence)
+ (1 − specificity) × (1 − prevalence))
This expression of PPV highlights the dependence of the
PPV on prevalence and permits the prediction of PPV across a
range of prevalences for a test with known sensitivity and
specificity.
Previous work from our group has reported sensitivities of
urine LCR testing in our laboratory of 88.6% to 95.5%, and
specificity of 99% for women.18 19 Given the dependence of PPV
on the prevalence and specificity, plots were constructed of the
predicted PPV across a range of plausible values for prevalence
(0.5%–10%) and specificity (95.0%–99.9%). The specificity
estimates represent a range that we would expect when the
tests are used in a variety of field settings outside the research
laboratory. We examined PPV at a sensitivity of 95.0% and
0.88.6%, but the effect of sensitivity on PPV was small. These
sensitivity estimates were used because they represent the
lower bounds of LCR sensitivity for diagnosis from urine in
earlier studies.
We compared the theoretically derived positive predictive
value of a single LCR result with the empirically observed PPV,
using a reference standard of “confirmed positive results”
(that is, positive on both first and second testing).
RESULTS
Theoretical expectation
Across a range of plausible prevalences and test characteris-
tics, the theoretical expectation for PPV of a single LCR testing
remained relatively low (fig 1). At 99.0% specificity and 95.0%
sensitivity, the PPV was 66% if population prevalence was 2%,
and it dropped to 32% if population prevalence was 0.5%. Even
if specificity were increased to 99.9%, PPV at 2% prevalence
was 95.1%, and at 0.5% prevalence it was 82.6%; a result that
predicts nearly one in five positive test results will be false
positive if true prevalence were as low as 0.5%. (Similar results
are obtained if sensitivity is assumed to be 88.6% instead of
95%; see results in fig 1.)
Empirical observations
In our field study, there were 579 eligible participants. Twenty
(3.5%) subjects initially tested positive for chlamydial
infection and 39 (6.7%) tested positive for gonococcal
infection. Retesting was performed on 19 of 20 positive
chlamydia specimens and 36 of 39 positive gonorrhoea speci-
mens. (No retests were available for two specimens that
initially tested positive for gonorrhoea and one specimen that
tested positive for both gonorrhoea and chlamydial infection.)
Retests yielded a second positive result in 17/19 (89.5%) cases
of chlamydial infection and 30/36 (83.3%) gonorrhoea cases.
These empirical results indicate that the positive predictive
values of the first LCR testing in our study were 89.5% for
chlamydial infection and 83.3% for gonorrhoea.
The unweighted prevalence of confirmed infections was
17/576 (3.0%) for chlamydial infection and 30/576 (5.2%) for
gonococcal infections. (The unweighted sample counts repre-
sent the results of our NAAT testing, they do not, however,
provide valid estimates of the prevalence of infection in the
population as a whole or in any subpopulation. Since we used
Figure 1 Calculated positive predictive values for a test with
sensitivity of 88.6%–95% and specificity of 95%–99.9% in
theoretical populations with disease prevalences of 0.0%–10.0%.
Note steep decrease in PPV at lower prevalence levels.
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a complex sample design which purposely oversampled
certain segments of the population (see Turner et al12), only the
weighted estimates can be used to make inferences about the
prevalence of NAAT detectable infections in the population.)
Assuming specificities for a single LCR testing to be
99.0%–99.6%, the theoretically expected PPV for a single LCR
testing for chlamydia would be 73%–87%, and for gonorrhoea
it would be 82%–92%. This theoretical expectation is in agree-
ment with our empirical results.
DISCUSSION
The availability of new, non-invasive NAATs (for example, LCR
and polymerase chain reaction (PCR)) for STDs has resulted in
recommendations to extend screening to venues of moderate
and low prevalence such as emergency departments, primary
care clinics, and others. Chlamydia testing is now recom-
mended as part of routine care for sexually active women
under 25 years of age. Using clinical tests to screen low preva-
lence populations presents new issues in the case of STD test-
ing. A positive STD test result has implications for treatment,
but it may also lead subjects to speculate about the source of
their infection. This speculation could lead to social or psycho-
logical stress, especially if the individual is in a perceived
monogamous relationship. Research and screening pro-
grammes that test low prevalence populations must reduce
both the incidence of false positives and ameliorate their con-
sequences.
Even under optimal conditions, unless the test specificity is
100%, clinicians will face the “epidemiological brick wall”
described in figure 1 and table 1. These false positive results
are predicted by Bayes’s theorem and are statistically
unavoidable unless test specificity is 100%, which is seldom,
if ever, attainable. Testing clinical specimens requires
execution of a series of steps including specimen collection,
transport, processing and detection, each of which is subject
to error. In the BSBS survey, 36 field interviewers were
employed to reach a population based sample of Baltimore
City residents. Considering the complexity of the logistics, we
were pleased with the diagnostic test’s performance on a sin-
gle testing. The number of false positives that we observed in
this study using repeat LCR testing were predictable based on
test characteristics and the low prevalence of infection in the
population.
Limitation of study
Our estimates of the PPV of LCR testing for gonococcal and
chlamydial infection are limited by the absence of an
independent “perfect” reference standard. We used as a refer-
ence standard a “confirmed positive result” based on initial
and repeat LCR testing using the same specimen and the same
test procedure. The use of the same test on the same specimen
has the potential to misclassify some positive results, because
a false positive test may be repeatedly false positive. Therefore,
our empirical determination of the PPV for a single LCR test-
ing might be viewed as the upper limit of the PPV for these
tests because a small number of false positive results could go
undetected with this testing scheme.
Recommendations
When clinical decisions are to be made based on test results
from the screening of a low prevalence population, we believe
that confirmatory algorithms are necessary. Repeat testing of
positives will increase specificity and reduce the incidence of
false positive test results. Ideally, a different, highly specific
and sensitive test should be used as the confirmation. An ini-
tial testing with LCR might, for example, be confirmed by a
repeat assay with PCR.
Since no testing protocol will completely eliminate the
threat of false positives, it will also be important to inform
subjects with confirmed positive test results of the possibility
of test error. This is a tricky task since we do not wish to dis-
courage subjects from seeking treatment. In the BSBS, we
eventually settled upon a script that:
(1) informed subjects that the tests are approved by the FDA
and have been found to be very reliable, but there was always
the possibility for error with any test; and
(2) if the respondent had doubts about the test result,
offered—at study expense—to collect another urine specimen
and test it.
For all respondents except those who requested additional
testing, we emphasised the importance of obtaining treatment
and, as before, provided them with the address of the
Baltimore public health clinic that would provide free,
expedited treatment, if they did not have a private physician
they wished to use.
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Table 1 Calculated PPV for theoretical populations with of prevalence of
0.5%–10% and test specificity of 98%–99.5%
Prevalence PPV at 98% Spec PPV @ 99% Spec PPV @ 99.5% Spec PPV @ 99.9% Spec
10% 84.1 91.3 95.4 99.1
5% 71.4 83.3 90.1 98.0
2% 49.2 65.9 79.4 95.1
1% 32.4 48.9 65.7 90.5
0.5% 19.2 32.3 48.8 82.6
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